000282578 001__ 282578
000282578 005__ 20251218103443.0
000282578 0247_ $$2doi$$a10.1186/s40644-025-00959-w
000282578 0247_ $$2pmid$$apmid:41275261
000282578 0247_ $$2pmc$$apmc:PMC12670812
000282578 0247_ $$2ISSN$$a1470-7330
000282578 0247_ $$2ISSN$$a1740-5025
000282578 037__ $$aDZNE-2025-01338
000282578 041__ $$aEnglish
000282578 082__ $$a610
000282578 1001_ $$aWinkelmann, Michael$$b0
000282578 245__ $$aPredictive value of maximum tumor dissemination (Dmax) in lymphoma patients treated with CD19-specific CAR T-Cells.
000282578 260__ $$aLondon$$bBioMed Central$$c2025
000282578 3367_ $$2DRIVER$$aarticle
000282578 3367_ $$2DataCite$$aOutput Types/Journal article
000282578 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1764937691_11989
000282578 3367_ $$2BibTeX$$aARTICLE
000282578 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000282578 3367_ $$00$$2EndNote$$aJournal Article
000282578 520__ $$aCD19-specific chimeric antigen receptor T-cell therapy (CART) has emerged as effective treatment for relapsed or refractory (r/r) lymphoma. The maximum distance (Dmax) of lymphoma lesions holds potential as prognostic imaging biomarker in lymphoma treated with conventional therapies, but evidence in the context of CART remains scarce and further studies are needed to clarify its clinical relevance. We evaluated Dmax at baseline imaging as a potential prognostic tool for assessment of metabolic and overall response, progression-free survival (PFS) and overall survival (OS).Consecutive r/r lymphoma patients with (PET/)CT imaging at baseline (BL) before lymphodepletion and subsequent CAR T-cell transfusion were included. Dmax was measured in cm at BL. Patients were divided by tertiles into three equal sized groups according to Dmax. Ann Arbor stages were calculated at baseline and the sum of product diameters (SPD) was used to represent tumor burden (TB). Overall response according to Lugano criteria and the Deauville score were determined at day 90 PET/CT imaging.Thirty-nine patients met the inclusion criteria. Median Dmax was 40.0 cm (IQR: 16.4-70.3 cm) at BL. Median TB decreased from BL with 4,095 mm2 to 770 mm2 at FU imaging. Median TB at BL was significantly higher in the Dmax intermediate and high group compared to the Dmax low group (p = 0.005) with 7,222 mm2 (IQR: 3,355-11,941 mm2), 4,649 mm2 (IQR: 2,376-10,406 mm2) and 1,739 mm2 (IQR: 715-7,402 mm2), respectively. Dmax intermediate and high group showed significantly higher Ann Arbor stages (p < 0.001). The survival analysis revealed a significantly (p = 0.030) shorter PFS in the Dmax high group compared to the other patients (91 vs. 364 days), but no relevant differences in OS (p = 0.151).Patients with high Dmax showed a shorter PFS, but no significant differences in OS. Dmax is a useful parameter for characterizing tumor dissemination, which could also be incorporated into scores due to its interval scale.
000282578 536__ $$0G:(DE-HGF)POF4-352$$a352 - Disease Mechanisms (POF4-352)$$cPOF4-352$$fPOF IV$$x0
000282578 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000282578 650_7 $$2Other$$a18F-FDG PET/CT
000282578 650_7 $$2Other$$aAnn-Arbor, Deauville-Score
000282578 650_7 $$2Other$$aCAR t-cell therapy
000282578 650_7 $$2Other$$aDissemination features
000282578 650_7 $$2Other$$aDmax, Dmaxbulk
000282578 650_7 $$2Other$$aLugano criteria
000282578 650_7 $$2Other$$aLymphoma
000282578 650_7 $$2NLM Chemicals$$aAntigens, CD19
000282578 650_7 $$2NLM Chemicals$$aReceptors, Chimeric Antigen
000282578 650_2 $$2MeSH$$aHumans
000282578 650_2 $$2MeSH$$aMale
000282578 650_2 $$2MeSH$$aFemale
000282578 650_2 $$2MeSH$$aMiddle Aged
000282578 650_2 $$2MeSH$$aImmunotherapy, Adoptive: methods
000282578 650_2 $$2MeSH$$aPositron Emission Tomography Computed Tomography: methods
000282578 650_2 $$2MeSH$$aAged
000282578 650_2 $$2MeSH$$aAntigens, CD19: immunology
000282578 650_2 $$2MeSH$$aAdult
000282578 650_2 $$2MeSH$$aLymphoma: therapy
000282578 650_2 $$2MeSH$$aLymphoma: pathology
000282578 650_2 $$2MeSH$$aLymphoma: diagnostic imaging
000282578 650_2 $$2MeSH$$aLymphoma: immunology
000282578 650_2 $$2MeSH$$aPrognosis
000282578 650_2 $$2MeSH$$aReceptors, Chimeric Antigen: immunology
000282578 650_2 $$2MeSH$$aTumor Burden
000282578 650_2 $$2MeSH$$aAged, 80 and over
000282578 650_2 $$2MeSH$$aRetrospective Studies
000282578 650_2 $$2MeSH$$aPredictive Value of Tests
000282578 7001_ $$aAchhammer, Philipp$$b1
000282578 7001_ $$aBlumenberg, Viktoria$$b2
000282578 7001_ $$aRejeski, Kai$$b3
000282578 7001_ $$aBücklein, Veit L$$b4
000282578 7001_ $$aSchmidt, Christian$$b5
000282578 7001_ $$aSheikh, Gabriel T$$b6
000282578 7001_ $$0P:(DE-2719)9001539$$aBrendel, Matthias$$b7$$udzne
000282578 7001_ $$aRicke, Jens$$b8
000282578 7001_ $$avon Bergwelt-Baildon, Michael$$b9
000282578 7001_ $$aSubklewe, Marion$$b10
000282578 7001_ $$aKunz, Wolfgang G$$b11
000282578 773__ $$0PERI:(DE-600)2104862-9$$a10.1186/s40644-025-00959-w$$gVol. 25, no. 1, p. 135$$n1$$p135$$tCancer imaging$$v25$$x1470-7330$$y2025
000282578 8564_ $$uhttps://pub.dzne.de/record/282578/files/DZNE-2025-01338.pdf$$yOpenAccess
000282578 8564_ $$uhttps://pub.dzne.de/record/282578/files/DZNE-2025-01338.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000282578 909CO $$ooai:pub.dzne.de:282578$$popenaire$$popen_access$$pVDB$$pdriver$$pdnbdelivery
000282578 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001539$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b7$$kDZNE
000282578 9131_ $$0G:(DE-HGF)POF4-352$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Mechanisms$$x0
000282578 9141_ $$y2025
000282578 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-02
000282578 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-01-02
000282578 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000282578 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2024-04-10T15:36:04Z
000282578 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2024-04-10T15:36:04Z
000282578 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-01-02
000282578 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2025-01-02
000282578 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-02
000282578 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000282578 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Peer review$$d2024-04-10T15:36:04Z
000282578 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2025-01-02
000282578 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-02
000282578 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2025-01-02
000282578 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-02
000282578 9201_ $$0I:(DE-2719)1110007$$kAG Haass$$lMolecular Neurodegeneration$$x0
000282578 980__ $$ajournal
000282578 980__ $$aVDB
000282578 980__ $$aUNRESTRICTED
000282578 980__ $$aI:(DE-2719)1110007
000282578 9801_ $$aFullTexts